XENE as reported
Xenon Pharmaceuticals Inc. reported $0 of revenue over the trailing twelve months, −100% on the year before. 9 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q1 2026 · −100% against the twelve months before
- Net Income
- −$383M
Net Income · +52% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$307M
Free Cash Flow · +54% year on year · trailing twelve months to Q1 2026
- EPS
- −$4.70
EPS · +46% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | −100% | Q1 2026 |
| Net Income | −$383M | +52% | Q1 2026 |
| EPS | −$4.70 | +46% | Q1 2026 |
| Op Margin | −8851% | n/a | Q3 2022 · 14 quarters behind |
| Net Margin | −8716% | n/a | Q3 2022 · 14 quarters behind |
| ROE | −47% | n/a | Q1 2026 |
| ROA | −43% | n/a | Q1 2026 |
| ROIC | 460% | n/a | Q1 2020 · 24 quarters behind |
| Free Cash Flow | −$307M | +54% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Xenon Pharmaceuticals Inc. (XENE) - Revenue & ProfitRevenue & ProfitXenon Pharmaceuticals Inc. (XENE)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com